Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on August 8, 2019. The filing reports the Company's financial results for the second quarter of 2019. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Global Market under the symbol ZFGN.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that financial results were announced and incorporates a press release (Exhibit 99.1) by reference, but the specific figures are not contained within the text of this Form 8-K.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the announcement of Q2 2019 results without providing comparative data in the body of the report.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors within the text provided. It notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting its legal incorporation into other filings unless expressly referenced.
Investor Verification Checklist
- Verify the specific Q2 2019 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 Press Release, as they are absent from this summary text.
- Confirm the Company name is Zafgen, Inc. (ZFGN), noting the discrepancy with the "Larimar Therapeutics" label in the request metadata.
- Review the full press release for any forward-looking statements or operational updates not captured in this brief 8-K notification.